Philadelphia, PA, United States of America

Scott M Lieberman


Average Co-Inventor Count = 4.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012-2014

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Scott M Lieberman: Innovator in Type 1 Diabetes Research

Introduction

Scott M Lieberman is a notable inventor based in Philadelphia, PA, who has made significant contributions to the field of type 1 diabetes research. He holds 2 patents that focus on the identification and treatment of antigens targeted by pathogenic T cells in this autoimmune condition. His work aims to improve the understanding and management of type 1 diabetes, which affects millions of individuals worldwide.

Latest Patents

Lieberman's latest patents include groundbreaking inventions related to antigens targeted by prevalent pathogenic T cells in type 1 diabetes. The first patent identifies a predominant ligand of CD8 T cells responsible for type 1 diabetes, specifically the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). This invention provides oligopeptide and polypeptide compositions that can bind to human MHC class I molecules, offering potential methods for treating mammals at risk for or diagnosed with type 1 diabetes. The second patent focuses on oligopeptide antigens to AI4-like T cells, providing methods for treating mammals with or at risk for type 1 diabetes using these antigens.

Career Highlights

Throughout his career, Scott M Lieberman has worked with prestigious institutions such as the Albert Einstein College of Medicine and the University of Virginia. His research has contributed to the advancement of knowledge in the field of immunology and diabetes, making him a respected figure among his peers.

Collaborations

Lieberman has collaborated with notable colleagues, including Teresa P DiLorenzo and Anne M Evans. These partnerships have further enriched his research and have led to innovative approaches in understanding and treating type 1 diabetes.

Conclusion

Scott M Lieberman is a distinguished inventor whose work in type 1 diabetes research has the potential to transform treatment options for those affected by this condition. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…